Oppenheimer Sees Apnimed's Ph2 Results Worth Watching for ResMed (RMD)
Tweet Send to a Friend
Oppenheimer analyst Suraj Kalia reiterated an Outperform rating and $312.00 price target on ResMed (NYSE: RMD) after the Apnimed announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
